Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 33.14% is in line with its 5-year average of 33.24%, around the middle of its 5-year range (12.62%–46.61%).
7.48% above its 12-month average of 30.83%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-07-31): 41.57%.
GROSS MARGIN
33.14%
GROSS MARGIN AVG TTM
30.83%
GROSS MARGIN AVG 3Y
33.54%
GROSS MARGIN AVG 5Y
33.24%
GROSS MARGIN AVG 10Y
18.46%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.48%
CURRENT VS 3Y AVG
-1.20%
CURRENT VS 5Y AVG
-0.32%
CURRENT VS 10Y AVG
+79.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-19.91%
vs the sector median at left
Market Cap
$80.68M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$81.15M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$79.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$79.24M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
50.00%
5Y Avg
38.04%
Market Cap
$82.42M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$81.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-39721.34%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nutriband Inc. (NTRB) | $79.99M | 33.14% | 30.83% | 33.54% | 33.24% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $81.15M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| vTv Therapeutics Inc. (VTVT)vs › | $79.24M | 0.00% | 50.00% | 50.00% | 38.04% |
| Humacyte, Inc. (HUMA)vs › | $82.42M | -736.46% | -368.23% | -290.99% | -1574.61% |
| MediciNova, Inc. (MNOV)vs › | $82.45M | 7.58% | 3.79% | 26.89% | 34.60% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $81.88M | 0.00% | 0.00% | 0.00% | -39721.34% |
| LENSAR Inc (LNSR)vs › | $83.02M | 47.96% | 47.37% | 50.31% | 51.06% |
| Outset Medical, Inc. (OM)vs › | $77.76M | 41.76% | 36.53% | 27.69% | 15.34% |
Gross Margin
33.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-07-31 | 41.57% |
| 2026-04-30 | 45.41% |
| 2026-01-31 | 22.20% |
| 2025-10-31 | 19.80% |
| 2025-07-31 | 25.20% |
| 2025-04-30 | 37.75% |
| 2025-01-31 | 42.75% |
| 2024-10-31 | 27.82% |
| 2024-07-31 | 20.51% |
| 2024-04-30 | 37.75% |
| 2024-01-31 | 32.45% |
| 2023-10-31 | 37.14% |
| 2023-07-31 | 45.69% |
| 2023-04-30 | 46.61% |
| 2023-01-31 | 24.53% |
| 2022-10-31 | 43.48% |
| 2022-07-31 | 33.28% |
| 2022-04-30 | 41.95% |
| 2022-01-31 | 21.01% |
| 2021-10-31 | 38.63% |
| 2021-07-31 | 12.62% |
| 2021-04-30 | 61.05% |
| 2021-01-31 | 53.54% |
| 2020-10-31 | 41.61% |
| 2020-07-31 | -38.47% |
| 2020-04-30 | 37.22% |
| 2020-01-31 | -544.78% |
| 2019-10-31 | -28.53% |
| 2019-07-31 | -57.46% |
| 2019-04-30 | -2.69% |
| 2019-01-31 | 0.55% |
| 2018-10-31 | -26.70% |
| 2018-07-31 | 0.00% |
| 2018-04-30 | 0.00% |
| 2018-01-31 | 0.00% |
| 2017-10-31 | 0.00% |
| 2017-07-31 | 0.00% |
| 2017-04-30 | 0.00% |
| 2017-01-31 | 0.00% |
| 2016-10-31 | 0.00% |
| 2016-07-31 | 0.00% |
| 2016-04-30 | 0.00% |
| 2016-01-31 | 0.00% |
